Lista de obras -

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

artículo científico publicado en 2016

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

artículo científico publicado en 2017

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

scientific article published on 03 November 2020

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

scientific article published on 03 April 2020

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

artículo científico publicado en 2020

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

artículo científico publicado en 2019

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

artículo científico publicado en 2020

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

scientific article published on 23 August 2020

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

artículo científico publicado en 2018

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

artículo científico publicado en 2012

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

artículo científico publicado en 2018

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

artículo científico publicado en 2018

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

artículo científico publicado en 2018

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

artículo científico publicado en 2016

Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy

artículo científico publicado en 2017

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

artículo científico publicado en 2016

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

artículo científico publicado en 2009

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

scholarly article by Anna Tasidou et al published 6 May 2012 in American Journal of Hematology

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

artículo científico publicado en 2010

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias

artículo científico publicado en 2011

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

artículo científico publicado en 2020

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

artículo científico publicado en 2015

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma

artículo científico publicado en 2015

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

artículo científico publicado en 2020

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

artículo científico publicado en 2019

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

artículo científico publicado en 2017

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

artículo científico publicado en 2020

Response to bortezomib of a patient with scleromyxedema refractory to other therapies

article

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

artículo científico publicado en 2010

Rituximab-based treatments in Waldenström's macroglobulinemia

scientific article published on March 2009

Screening for Gaucher disease among patients with plasma cell dyscrasias

artículo científico publicado en 2019

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy

TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma

artículo científico publicado en 2015

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

scientific article published on 25 September 2020

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

artículo científico publicado en 2017

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

artículo científico publicado en 2020

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

artículo científico publicado en 2007

Treatment of light chain deposition disease with bortezomib and dexamethasone

artículo científico publicado en 2009

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

artículo científico publicado en 2008

Lista de obras de

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

Response to bortezomib of a patient with scleromyxedema refractory to other therapies

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

Rituximab-based treatments in Waldenström's macroglobulinemia

Screening for Gaucher disease among patients with plasma cell dyscrasias

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy

TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

Treatment of light chain deposition disease with bortezomib and dexamethasone

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens